These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 27580907)

  • 21. Cognition, cognitive dysfunction, and cognitive rehabilitation in multiple sclerosis.
    Pepping M; Brunings J; Goldberg M
    Phys Med Rehabil Clin N Am; 2013 Nov; 24(4):663-72. PubMed ID: 24314684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anxiety and Depressive Symptoms Are Associated With Worse Performance on Objective Cognitive Tests in MS.
    Morrow SA; Rosehart H; Pantazopoulos K
    J Neuropsychiatry Clin Neurosci; 2016; 28(2):118-23. PubMed ID: 26569152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cognitive rehabilitation in multiple sclerosis.
    Longley WA
    Aust J Gen Pract; 2022 Apr; 51(4):233-237. PubMed ID: 35362007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option?
    Christodoulou C; MacAllister WS; McLinskey NA; Krupp LB
    CNS Drugs; 2008; 22(2):87-97. PubMed ID: 18193921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cognitive impairment in multiple sclerosis - a review of current knowledge and recent research.
    Grzegorski T; Losy J
    Rev Neurosci; 2017 Nov; 28(8):845-860. PubMed ID: 28787275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exercise as a Countermeasure to Declining Central Nervous System Function in Multiple Sclerosis.
    Motl RW; Sandroff BM
    Clin Ther; 2018 Jan; 40(1):16-25. PubMed ID: 29287750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The protective effects of high-education levels on cognition in different stages of multiple sclerosis.
    Rimkus CM; Avolio IMB; Miotto EC; Pereira SA; Mendes MF; Callegaro D; Leite CDC
    Mult Scler Relat Disord; 2018 May; 22():41-48. PubMed ID: 29554549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Focus on neglected features of cognitive rehabilitation in MS: Setting and mode of the treatment.
    Podda J; Tacchino A; Pedullà L; Monti Bragadin M; Battaglia MA; Brichetto G
    Mult Scler; 2022 Jun; 28(7):1009-1019. PubMed ID: 33045916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cognitive impairment in multiple sclerosis: "classic" knowledge and recent acquisitions.
    Piacentini C; Argento O; Nocentini U
    Arq Neuropsiquiatr; 2023 Jun; 81(6):585-596. PubMed ID: 37379870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Time matters: Early-phase multiple sclerosis is accompanied by considerable impairments across multiple domains.
    Thrue C; Riemenschneider M; Hvid LG; Stenager E; Dalgas U
    Mult Scler; 2021 Sep; 27(10):1477-1485. PubMed ID: 32613902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anticholinesterasics in the treatment of cognitive impairment in multiple sclerosis.
    Porcel J; Montalban X
    J Neurol Sci; 2006 Jun; 245(1-2):177-81. PubMed ID: 16674980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized controlled pilot trial: the effects of EGb 761 on information processing and executive function in multiple sclerosis.
    Diamond BJ; Johnson SK; Kaufman M; Shiflett SC; Graves L
    Explore (NY); 2013; 9(2):106-7. PubMed ID: 23452713
    [No Abstract]   [Full Text] [Related]  

  • 34. The association between intra- and juxta-cortical pathology and cognitive impairment in multiple sclerosis by quantitative T
    Louapre C; Govindarajan ST; Giannì C; Madigan N; Nielsen AS; Sloane JA; Kinkel RP; Mainero C
    Neuroimage Clin; 2016; 12():879-886. PubMed ID: 27872810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurological update: cognitive rehabilitation in multiple sclerosis.
    Chen MH; Chiaravalloti ND; DeLuca J
    J Neurol; 2021 Dec; 268(12):4908-4914. PubMed ID: 34028615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Return to flight with multiple sclerosis: aeromedical considerations.
    Zinger H; Grossman A; Assa A; Barel O; Barenboim E; Levite R
    Aviat Space Environ Med; 2011 Jan; 82(1):61-4. PubMed ID: 21235109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The relationships between apathy and executive dysfunction in multiple sclerosis.
    Raimo S; Trojano L; Spitaleri D; Petretta V; Grossi D; Santangelo G
    Neuropsychology; 2016 Sep; 30(6):767-74. PubMed ID: 27054440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between Social Cognition and traditional cognitive impairment in Progressive Multiple Sclerosis and possible implicated neuroanatomical regions.
    Ciampi E; Uribe-San-Martin R; Vásquez M; Ruiz-Tagle A; Labbe T; Cruz JP; Lillo P; Slachevsky A; Reyes D; Reyes A; Cárcamo-Rodríguez C
    Mult Scler Relat Disord; 2018 Feb; 20():122-128. PubMed ID: 29414284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is neuropsychological rehabilitation effective in multiple sclerosis?
    Hämäläinen P; Rosti-Otajärvi E
    Neurodegener Dis Manag; 2014; 4(2):147-54. PubMed ID: 24832032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal.
    D'Amico E; Leone C; Hayrettin T; Patti F
    Mult Scler; 2016 Apr; 22(5):581-9. PubMed ID: 26920381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.